HK1202310A1 - Single-stranded nucleic acid molecule having amino acid backbone - Google Patents

Single-stranded nucleic acid molecule having amino acid backbone

Info

Publication number
HK1202310A1
HK1202310A1 HK15102793.8A HK15102793A HK1202310A1 HK 1202310 A1 HK1202310 A1 HK 1202310A1 HK 15102793 A HK15102793 A HK 15102793A HK 1202310 A1 HK1202310 A1 HK 1202310A1
Authority
HK
Hong Kong
Prior art keywords
stranded nucleic
amino acid
nucleic acid
acid molecule
backbone
Prior art date
Application number
HK15102793.8A
Other languages
English (en)
Chinese (zh)
Inventor
Ohgi Tadaaki
Suzuki Hiroshi
Hamasaki Tomohiro
Aoki Eriko
Original Assignee
Bonac Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bonac Corp filed Critical Bonac Corp
Publication of HK1202310A1 publication Critical patent/HK1202310A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/04—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated
    • C07C225/06—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and acyclic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/532—Closed or circular
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/533—Physical structure partially self-complementary or closed having a mismatch or nick in at least one of the strands
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK15102793.8A 2012-01-07 2015-03-18 Single-stranded nucleic acid molecule having amino acid backbone HK1202310A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012001711 2012-01-07
JP2012026745 2012-02-09
PCT/JP2012/084247 WO2013103146A1 (fr) 2012-01-07 2012-12-29 Molécule d'acide nucléique simple brin ayant un squelette d'acides aminés

Publications (1)

Publication Number Publication Date
HK1202310A1 true HK1202310A1 (en) 2015-09-25

Family

ID=48745204

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15102793.8A HK1202310A1 (en) 2012-01-07 2015-03-18 Single-stranded nucleic acid molecule having amino acid backbone

Country Status (8)

Country Link
US (1) US9528111B2 (fr)
EP (1) EP2801617B1 (fr)
JP (1) JP5876890B2 (fr)
KR (1) KR101674778B1 (fr)
CN (2) CN104039961A (fr)
ES (1) ES2645996T3 (fr)
HK (1) HK1202310A1 (fr)
WO (1) WO2013103146A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104271742B (zh) 2012-03-04 2018-06-05 株式会社博纳克 微小rna抑制剂
US9663784B2 (en) 2012-05-26 2017-05-30 Bonac Corporation Single-stranded nucleic acid molecule for regulating expression of gene having delivering function
WO2015099122A1 (fr) 2013-12-26 2015-07-02 学校法人東京医科大学 Miarn mimétique artificiel pour contrôler l'expression génique, et son utilisation
CA2935022A1 (fr) * 2013-12-27 2015-07-02 Bonac Corporation Arnmi de type correspondance artificielle pour controler l'expression de genes et utilisation de celui-ci
WO2015099188A1 (fr) * 2013-12-27 2015-07-02 株式会社ボナック Micro-arn de type à correspondance artificielle pour le contrôle de l'expression génétique et son utilisation
EP3239297B1 (fr) * 2014-12-27 2021-03-10 Bonac Corporation Arnmi naturel pour le contrôle de l'expression génique, et son utilisation
US11142769B2 (en) 2015-03-27 2021-10-12 Bonac Corporation Single-stranded nucleic acid molecule having delivery function and gene expression regulating ability
CA3002786C (fr) * 2015-10-30 2021-09-07 Bonac Corporation Composition contenant sous forme stable une molecule d'acide nucleique simple brin qui supprime l'expression du gene tgf-s1
AU2017211461B2 (en) * 2016-01-26 2023-01-12 Nissan Chemical Corporation Single-stranded oligonucleotide
CN109072224B (zh) * 2016-01-30 2022-07-15 株式会社博纳克 人工单导rna及其用途
CN110337495B (zh) * 2017-02-06 2024-03-29 日产化学株式会社 单链寡核苷酸
US20200038427A1 (en) * 2017-03-31 2020-02-06 Bonac Corporation Cyclic nucleic acid molecule having gene expression control function
KR20200033927A (ko) 2017-07-28 2020-03-30 교린 세이야꾸 가부시키 가이샤 섬유증 치료제
JPWO2019074110A1 (ja) * 2017-10-13 2020-12-24 株式会社ボナック 一本鎖核酸分子およびその製造方法
TWI830718B (zh) * 2018-02-09 2024-02-01 日商住友化學股份有限公司 核酸分子之製造方法
AU2019237599A1 (en) 2018-03-20 2020-11-12 Nissan Chemical Corporation Antisense oligonucleotide having reduced toxicity
WO2019189591A1 (fr) * 2018-03-30 2019-10-03 住友化学株式会社 Procédé de production d'arn simple brin
RU2020130258A (ru) 2018-03-30 2022-05-04 Торэй Индастриз, Инк. Способ получения шпилечной одноцепочечной молекулы рнк
JP7405086B2 (ja) 2018-10-02 2023-12-26 東レ株式会社 ヘアピン型一本鎖ｒｎａ分子の製造方法
WO2020202952A1 (fr) 2019-03-29 2020-10-08 住友化学株式会社 Support poreux inorganique et procédé de production d'acide nucléique l'utilisant
WO2020202949A1 (fr) 2019-03-29 2020-10-08 住友化学株式会社 Procédé de production d'arn
WO2020202953A1 (fr) 2019-03-29 2020-10-08 住友化学株式会社 Support poreux inorganique et procédé de production d'acide nucléique l'utilisant
US20220106347A1 (en) 2019-03-29 2022-04-07 Sumitomo Chemical Company, Limited Porous inorganic carrier and method for producing nucleic acid using same
US20220153774A1 (en) 2019-03-29 2022-05-19 Sumitomo Chemical Company, Limited Inorganic porous carrier and method for producing nucleic acids using same
WO2021193954A1 (fr) * 2020-03-27 2021-09-30 住友化学株式会社 Procédé pour la production d'oligomères d'acides nucléiques
KR20230009901A (ko) 2020-05-13 2023-01-17 스미또모 가가꾸 가부시끼가이샤 무기 다공질 기재, 무기 다공질 담체, 및 핵산의 제조 방법
US20230357767A1 (en) * 2020-08-25 2023-11-09 Bonac Corporation Novel nucleic acid molecule inhibiting expression of target gene
EP4219520A4 (fr) 2020-09-24 2024-09-18 Sumitomo Chemical Co Procédé de production d'un oligomère d'acide nucléique

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE873543C (de) * 1942-10-28 1953-04-16 Basf Ag Verfahren zur Herstellung von hydroxyl- bzw. sulfhydryl-gruppenhaltigen Dicarbaminsaeureestern
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4550163A (en) 1979-02-05 1985-10-29 Abbott Laboratories Ligand analog-irreversible enzyme inhibitor conjugates
US20030232355A1 (en) * 1992-05-22 2003-12-18 Isis Pharmaceuticals, Inc. Double-stranded peptide nucleic acids
US6509323B1 (en) 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
US6852334B1 (en) * 1999-04-20 2005-02-08 The University Of British Columbia Cationic peg-lipids and methods of use
TWI321054B (en) 2000-12-19 2010-03-01 California Inst Of Techn Compositions containing inclusion complexes
DK1412517T3 (da) 2001-03-09 2007-03-05 Boston Probes Inc Fremgangsmåder, kits og sammensætninger af kombinationsoligomerer
WO2003037909A1 (fr) 2001-10-29 2003-05-08 Mcgill University Oligonucleotides contenant un lieur acyclique et utilisations associees
AU2003256857A1 (en) 2002-08-08 2004-02-25 Dharmacon, Inc. Short interfering rnas having a hairpin structure containing a non-nucleotide loop
JP2007516695A (ja) * 2003-06-12 2007-06-28 アプレラ コーポレイション ユニバーサル塩基アナログを含む組合せ核酸塩基オリゴマーならびにこれらを作製する方法および使用する方法
CN1860228B (zh) * 2003-09-30 2010-04-28 安琪士摩奇株式会社 订书钉型寡核苷酸及包含该订书钉型寡核苷酸的药物
MX2007008065A (es) * 2004-12-30 2008-03-04 Todd M Hauser Composiciones y metodos para modular la expresion genica usando oligonucleotidos autoprotegidos.
EP2233573B1 (fr) * 2007-11-29 2013-10-23 Suzhou Ribo Life Science Co., Ltd Molécule complexe interférant avec l'expression de gènes cibles, et ses méthodes de préparation
WO2009076321A2 (fr) * 2007-12-07 2009-06-18 Halo-Bio Rnai Therapeutics Inc. Compositions et procédés pour moduler une expression génique en utilisant des polynucléotides de précurseur asymétriquement actifs
CA2768598A1 (fr) * 2009-07-22 2011-01-27 Cenix Bioscience Gmbh Systeme d'administration et conjugues pour l'administration de composes par des voies de transport intracellulaire naturelles

Also Published As

Publication number Publication date
US20140329886A1 (en) 2014-11-06
CN110055247A (zh) 2019-07-26
EP2801617B1 (fr) 2017-09-06
CN104039961A (zh) 2014-09-10
ES2645996T3 (es) 2017-12-11
JP5876890B2 (ja) 2016-03-02
EP2801617A4 (fr) 2015-09-30
EP2801617A1 (fr) 2014-11-12
JPWO2013103146A1 (ja) 2015-05-11
WO2013103146A1 (fr) 2013-07-11
KR101674778B1 (ko) 2016-11-09
KR20140111688A (ko) 2014-09-19
US9528111B2 (en) 2016-12-27

Similar Documents

Publication Publication Date Title
HK1202310A1 (en) Single-stranded nucleic acid molecule having amino acid backbone
HK1244509A1 (zh) 包含鎖核酸基序的基於寡核苷酸的抑制劑
EP2917372A4 (fr) Séquençage d'acide nucléique à l'aide d'étiquettes
IL231983B (en) Dna containing tricyclo-phosphorothioate
SG11201405542UA (en) Artificial nucleic acid molecules
EP2799548A4 (fr) Acide nucléique antisens
GB201204407D0 (en) Nucleic acid molecule
RS62530B1 (sr) Sastavi za sekvenciranje nukleinskih kiselina
EP2729182A4 (fr) Complexe d'acide nucléique
ZA201205891B (en) Dna polymerases
EP2694683A4 (fr) ACIDES NUCLÉIQUES GAMMA-PEPTIDIQUES CONTENANT DU MiniPEG, CONFORMATIONNELLEMENT PRÉORGANISÉS
EP2705162A4 (fr) Procédé de détection de variants dans une séquence d'acide nucléique
EP2691522A4 (fr) Molécule d'acide nucléique fonctionnelle et ses applications
HK1216653A1 (zh) 多重核酸檢測方法
EP2764112A4 (fr) Analyse directe d'acides nucléiques
GB201118636D0 (en) Nucleotide sequence
GB2503856B (en) Methods for nucleic acid purification
EP2902488A4 (fr) Adn polymérase modifiée
EP2915815A4 (fr) Acide nucléique modifié inédit
HK1245104A1 (zh) Dna疫苗
EP2798092A4 (fr) Sondes d'hybridation d'acide nucléique
EP2700414A4 (fr) Acide nucléique auto-gélatinisable
EP2844772A4 (fr) Séquençage d'adn
EP2682462A4 (fr) Complexe (acide nucléique)-polysaccharide
EP2702065A4 (fr) Extraction d'adn dans la purification de molécule cible

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20221225